In this downloadable slideset, expert faculty provide a comprehensive update on HCV therapy.
In this downloadable slideset, expert faculty provide a comprehensive update on managing HCV in special patient populations.
Led by Paul Martin, MD, a panel of experts discusses their management approach to several controversial clinical scenarios, including whether to treat patients with immune-tolerant HBV infection, whether all patients receiving suppressive TDF for the treatment of HBV infection should be switched to TAF, if it is reasonable to discontinue oral therapy in select patients with HBeAg-negative HBV infection who do not have cirrhosis, and whether increased engagement by liver disease specialists will be needed to reach HCV elimination goals by 2030.
Led by Christian B. Ramers, MD, MPH, a panel of experts discusses their management approaches to challenging patient case scenarios, including a patient with decompensated cirrhosis and chronic HCV infection, a patient with suspected acute HCV infection and recent injection drug use, a DAA-experienced patient with genotype 1a HCV infection, and a patient with suppressed HBV infection and treated and cured HCV infection who has persistent liver enzyme elevations.
Annenberg Center for Health Sciences at Eisenhower
39000 Bob Hope Dr
Dinah Shore Bldg.
Rancho Mirage, CA 92270
Melissa Velasquez, Accreditation Specialist
(760) 773-4506
(760) 773-4550 (Fax)
ce@annenberg.net
http://www.annenberg.net/
You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.